 |
|
Glucocorticoid Use and Risk of Atrial Fibrillation or FlutterA Population-Based, Case-Control Study
Christian Fynbo Christiansen, MD;
Steffen Christensen, MD;
Frank Mehnert, MSc;
Steven R. Cummings, MD;
Roland D. Chapurlat, MD, PhD;
Henrik Toft Sørensen, MD, PhD, DMSc
Arch Intern Med. 2009;169(18):1677-1683.
Background Glucocorticoid use is associated with increased risk of myocardial infarction, stroke, and heart failure, but data are limited on the risk of atrial fibrillation or flutter. We examined whether glucocorticoid use is associated with the risk of atrial fibrillation or flutter.
Methods For this population-based, case-control study, we identified all patients with a first hospital diagnosis of atrial fibrillation or flutter from January 1, 1999, through December 31, 2005, in Northern Denmark (population, 1.7 million). For each case we selected 10 population controls matched by age and sex. We obtained data on glucocorticoid prescriptions within 60 days (current users) or longer before the index date (former users), comorbidity, and medications from medical databases. We used conditional logistic regression to compute odds ratios (ORs), controlling for potential confounders.
Results Among 20 221 patients with atrial fibrillation or flutter, 1288 (6.4%) were current glucocorticoid users and 2375 (11.7%) were former users. Among 202 130 population controls, 5245 (2.6%) were current glucocorticoid users and 19 940 (9.9%) were former users. Current glucocorticoid use was associated with an increased risk of atrial fibrillation or flutter compared with never use (adjusted OR, 1.92; 95% confidence interval [CI], 1.79-2.06). Among new glucocorticoid users, the adjusted OR was 3.62 (95% CI, 3.11-4.22) and among long-term users it was 1.66 (95% CI, 1.53-1.80). The increased risk remained robust in patients with and without pulmonary and cardiovascular diseases. Former glucocorticoid use was not associated with increased risk (adjusted OR, 1.00; 95% CI, 0.96-1.06).
Conclusion Current glucocorticoid use was associated with an almost 2-fold increased risk of atrial fibrillation or flutter.
Author Affiliations: Departments of Clinical Epidemiology (Drs Christiansen, Christensen, and Sørensen and Mr Mehnert) and Anesthesiology and Intensive Care Medicine (Dr Christiansen), Aarhus University Hospital, Aarhus, Denmark; San Francisco Coordinating Center, California (Dr Cummings); and Institut National de la Santé et la Recherche Médicale Research Unit 831, Université de Lyon, and Department of Orthopedics and Rheumatology, Hôpital Edouard Herriot, Lyon, France (Dr Chapurlat).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(18):1648.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study
Schmidt et al.
BMJ 2011;343:d3450-d3450.
ABSTRACT
| FULL TEXT
Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention
Savelieva et al.
Europace 2011;13:308-328.
ABSTRACT
| FULL TEXT
A Case of Atrial Fibrillation Induced by Inhaled Fluticasone Propionate
Oteri et al.
Pediatrics 2010;126:e1237-e1241.
ABSTRACT
| FULL TEXT
Corticosteroid Therapy After Catheter Ablation of Atrial Fibrillation for an Authentic "Blanking Period"
Belhassen
J Am Coll Cardiol 2010;56:1473-1475.
FULL TEXT
Advances in Population-Based Studies
Truelsen
Stroke 2010;41:e99-e101.
FULL TEXT
Glucocorticoid Use Is Associated with Risk for Atrial Fibrillation
JWatch General 2009;2009:8-8.
FULL TEXT
|
